[1] 白耀. 甲状腺病学-基础与临床.北京:科学技术文献出版社,2003.244-636.
[2] 张承刚. 主编.甲状腺疾病核素治疗学.北京:原子能出版社,2003.166-349.
[3] Bolanos F,Gonzalez-Ortiz M,Duron H,et al. Remission of Graves' hyperthyroidism treated with methimazole.Rev Invest Clin,2002,54(4):307-310.
[4] Menendez E,Anda E,Barberia JJ,et al. Recurrence and prognostic factors after treatment with antithyroid agents in Graves-Basedow disease.Multicenter study in Northern Spain.Rev Clin Esp,2000,200(2):69-73.
[5] Quadbeck B,Hoermann R,Roggenbuck U,et al. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.Thyroid,2005,15(9):1047-1054.
[6] Cooper DS. Hyperthyroidism.Lancet,2003,362(9382):459-468.
[7] Cooper DS. Antithyroid Drugs.N Engl J Med,2005,352(9):905-917.
[8] Woeber KA. Methimazole-induced hepatotoxicity.Endocr Pract,2002,8(3):222-224.
[9] 高莹,赵明辉,叶华,等. 19例丙基硫氧嘧啶引起抗中性粒细胞胞浆抗体相关小血管炎的临床分析.中华内分泌代谢杂志,2006,22(2):124-126.
[10] Gao Y,Zhao MH,Guo XH,et al. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies(ANCA) in Chinese patients with hyperthyroidism.Endocr Res,2004,(3002):205-213.
[11] Guma M,Salinas I,Reverter JL,et al. Frequency of antineutrophil cytoplasmic antibody in Graves' disease patients treated with methimazole.J Clin Endocrionl Metab,2003,88(5):2141-2146.
[12] Streetman DD,Khanderia U. Diagnosis and treatment of Graves disease.Ann Pharmacother,2003,37(7-8):1100-1109.
[13] Ginsberg J. Diagnosis and management of Graves' disease.CMAJ,2003,168(5):575-585.
[14] Giovanella L,De Palma D,Ceriani L,et al. Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach.Clinical results. Radiol Med(Torino),2000,100(6):480-483.
[15] Metso S,Jaatinen P,Huhtala H,et al. Long-term follow-up study of radioiodine treatment of hyperthyroidism.Clin Endocrinol(Oxf),2004,61(5):641-648.
[16] Santos RB,Romaldini JH,Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease.Thyroid,2004,14(7):525-530.
[17] 康增寿,戴维信,杜永昌. 131I治疗儿童Graves'甲亢安全、有效.国外医学·放射医学核医学分册,2001,25(4):149-152.
[18] Stocker DJ,Foster SS,Solomon BL,et al. Thyroid cancer yield in patients with Graves' disease selected for surgery on the basis of cold scintiscan defects.Thyroid,2002,12(4):305-311.
[19] Franklyn JA. The management of hyperthyroidism.N Engl J Med,1994,330(24):1731-1738.
[20] 邢家骝.主编.131碘治疗甲状腺疾病.北京:人民卫生出版社,2002.265-267.
[21] Gittoes NJ,Franklyn JA. Current treatment guidelines.Drugs,1998,55(4):543-553.
[22] Abraham P,Avenell A,Park GM,et al. A systematic review of drug therapy for Graves' hyperthyroidism.Eur J Endocrinol,2005,153(4):489-498.
[23] Andrade VA,Gross JL,Maia AL. Radioactive iodine therapy in Graves' hyperthyroidism.Arq Bras Endocrinol Metabol,2004,48(1):159-165.
[24] Reiners C. Radioiodine therapy for Graves' disease:problems and new developments.Z Arztl Fortbild Qualitatssich,2004,98(suppl 5):55-62.
[25] Azizi F,Ataie L,Hedayati M,et al. Effect of long-term continuous methimazole treatment of hyperthyroidism:comparison with radioiodine.Eur J Endocrinol,2005,152(5):695-701.